MRI-guided ultrasound inferior for certain myomas

Article

Magnetic resonance-guided focused ultrasound surgery (MRgFUS), which is the least invasive surgical method for treating uterine myomas, is not ideal for type 3 high-intensity myomas.

Magnetic resonance-guided focused ultrasound surgery (MRgFUS), which is the least invasive surgical method for treating uterine myomas, is not ideal for type 3 high-intensity myomas. That's the case because the treated area ratio immediately after the procedure is small compared with that for type 1 and 2 myomas, and the subsequent volume change is unfavorable, according to the results of a prospective study from Japan.

The authors of the study followed 48 myomas in 35 women with MR images for 6 months after MRgFUS and followed 23 myomas in 17 women for 12 months after MRgFUS.

They found that while some type 1 and 2 myomas had reduced perfused volume 6 months after the procedure, all type 3 myomas showed increased perfused volume at 6 months post-MRgFUS, indicating, as has been previously suggested, that type 3 myoma cells naturally resist focused ultrasound energy and heating effects.

Funaki K, Fukunishi H, Funaki T, et al. Mid-term outcome of magnetic resonance-guided focused ultrasound surgery for uterine myomas: from six to twelve months after volume reduction. J Minim Invasive Gynecol. 2007;14:616-621.

Recent Videos
HPV self-collection: Benefits, limitations, and future implications | Image Credit: forhers.com
Improving pediatric HPV vaccination rates: Early initiation and addressing disparities | Image Credit: blog.nemours.org.
New cervical cancer screening guidelines: What practitioners needs to know | Image Credit: forhers.com
COVID-19 Therapy Roundtable: Focusing on inpatient care
COVID-19 Therapy Roundtable: Defining the virus today and treatment options
How fezolinetant advances non-hormonal treatment of hot flashes | Image Credit: medschool.cuanschutz.edu
Contraceptive access challenges for college students in contraception deserts | Image Credit: linkedin.com.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.